Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus BREO ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus BREO ELLIPTA.
ACTICORT vs BREO ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Category C
Category C
Corticosteroid
Corticosteroid/Beta-2 Agonist Combination